8-K: MDWerks Expands Board, Appoints Jeff Hopmayer

MDWerks, Inc. announced the appointment of Jeff Hopmayer to its Board of Directors as the company focuses on commercial execution of its molecular targeting technology platform.

Summary

• MDWerks, Inc. has expanded its Board of Directors from five to six members.
• Jeffrey Scott Hopmayer has been appointed as an independent director, effective July 9, 2026.
• Mr. Hopmayer's appointment follows an Independent Director Agreement entered into on June 26, 2026, with a three-year term.
• He will receive $5,000 per quarter and be issued 500,000 shares of common stock upon commencement.
• Additionally, he will receive a quarterly bonus of shares equivalent to $30,000 based on a VWAP schedule.
• The company's molecular targeting technology platform is valued at approximately $400 million, supported by a global patent estate.
• MDWerks is transitioning from technology development to commercial execution, with initial customer deployments beginning in Q2 2026.
• The technology has been commercialized in the beverage alcohol industry and expanded into the wood products industry with its Molecular Sawdust Drying System (MSDS).
• The company sees significant opportunities in various industrial markets, estimating the addressable market at over $1.8 trillion globally.
• A press release on July 10, 2026, also announced the appointment of Roy Milner to the Board of Directors.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, highlighting the addition of experienced leadership and the company's strategic focus on commercialization and platform expansion, supported by significant IP valuation and early market traction.

Positives

• Expansion of the Board of Directors with an experienced independent director, Jeff Hopmayer.
• Appointment of Jeff Hopmayer, a nationally recognized entrepreneur and investor, to the Board.
• Independent Director Agreement with Mr. Hopmayer includes a three-year term, quarterly compensation, and significant stock issuance (500,000 shares plus quarterly bonuses).
• The company's molecular targeting technology platform is independently appraised at approximately $400 million.
• Commercial contracts are signed, and customer deployments began in Q2 2026.
• The company is executing a strategy focused on recurring licensing revenue and scalable industrial applications.
• The technology platform is protected by a broad global patent estate.
• Successful expansion into a second commercial vertical (wood products) with the Molecular Sawdust Drying System (MSDS).
• Significant estimated addressable markets of over $1.8 trillion globally for current and potential applications.
• Management believes the technology platform has broad applicability across numerous industrial sectors.

Negatives

• The company is transitioning from technology development to commercial execution, indicating it is still in an early stage of commercialization.
• The filing does not provide specific financial metrics for revenue, profit, or EBITDA, making it difficult to assess current financial performance.
• The stock is traded on OTCQB (MDWK), which typically indicates a lower liquidity and higher risk profile compared to major exchanges.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially.
• The company cautions that forward-looking statements are subject to risks and uncertainties described in its Form 10-K and 10-Q filings.
• The success of the company relies on its ability to expand its proprietary molecular targeting platform into additional industrial sectors.
• The company's business model is dependent on a scalable licensing model, which requires successful adoption and recurring revenue generation.

Future Outlook

The company is focused on commercial execution, aiming for recurring licensing revenue and scalable industrial applications. Management believes the technology platform has significant opportunities across multiple industrial markets, with an estimated addressable market exceeding $1.8 trillion globally. The company is transitioning from innovation to commercialization and aims to expand strategic partnerships, accelerate commercial adoption, and broaden recurring licensing opportunities.

Management Comments

• "What attracted me to MDWerks is that it isnt simply commercializing a productits commercializing a molecular targeting technology platform. The ability to selectively influence target molecules creates opportunities to enhance manufacturing processes across numerous industries. Once a platform demonstrates value in one industry and then successfully expands into another, such as wood products, it begins to validate a much larger opportunity. Companies capable of repeatedly solving complex industrial challenges across multiple markets are relatively uncommon. MDWerks has assembled a highly differentiated technology platform supported by a substantial patent estate, demonstrated early commercial traction, and is now transitioning from innovation to commercialization. I look forward to working alongside management and my fellow directors as we expand strategic partnerships, accelerate commercial adoption, broaden recurring licensing opportunities, and continue unlocking the value of this platform for customers and shareholders alike."
• "Jeff has consistently demonstrated an ability to recognize transformational opportunities and help companies bridge the gap between innovation and commercial execution. His experience building businesses, creating strategic partnerships, and commercializing emerging technologies makes him an outstanding addition to our Board as MDWerks continues evolving from a technology developer into a platform company serving multiple industrial markets."

Industry Context

StockSavvy.ai notes that MDWerks' strategy of developing a versatile molecular targeting technology platform and leveraging a licensing model aligns with trends in deep tech commercialization. The expansion into diverse industrial markets, from beverage alcohol to wood products and beyond, suggests a focus on platform scalability, a key differentiator in the industrial technology sector. The company's emphasis on a strong patent estate and an independently appraised IP portfolio of $400 million underscores the value placed on proprietary technology in securing market position and attracting investment.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased long-term shareholder value through successful commercialization, licensing revenue, and expansion into large addressable markets. Stock issuance to new director may dilute existing shareholders.
• Employees: Continued focus on commercial execution may lead to growth and new opportunities within the company.
• Customers: Potential for improved industrial processes, product quality, sustainability, and manufacturing economics through the company's technology.
• Suppliers: Increased commercial activity could lead to greater demand for raw materials or services.
• Creditors: The company's transition to a revenue-generating model could improve its financial stability.

Next Steps

• Expand strategic partnerships.
• Accelerate commercial adoption of the molecular targeting platform.
• Broaden recurring licensing opportunities.
• Continue unlocking the value of the platform for customers and shareholders.
• Work with management on corporate strategy, partnerships, commercialization initiatives, mergers and acquisitions, capital formation, and identifying opportunities to expand the platform into additional industrial sectors.

Key Dates

Recommendation

The filing indicates positive strategic developments with the appointment of experienced directors and a clear focus on commercializing a valuable technology platform with significant market potential. However, the lack of detailed financial performance metrics and the OTCQB listing suggest a need for caution. A 'hold' recommendation is appropriate pending further financial disclosures and evidence of sustained commercial traction and revenue growth.

Keywords

MDWerks, 8-K, Board of Directors, Independent Director, Jeff Hopmayer, Molecular Targeting Technology, Commercialization, Licensing Revenue, Intellectual Property, Patent Estate, Industrial Markets, Wood Products, Beverage Alcohol, OTCQB: MDWK